Lots to look forward to' as ReNeuron gets go-ahead for phase IIb stroke trial - Michael Hunt, Chief Financial Officer, ReNeuron Group 00:00:00

Share On Facebook Share On Twitter

ReNeuron Group (RENE) is a biotechnology firm. The principal of the business involves the research and development of stem cell technology for the treatment of motor disabilities and blindness-causing diseases.

Recent Videos